Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Citadel Group Major Shareholding Notification 2023

Jun 26, 2023

10454_mrq_2023-06-26_80d4d281-04c8-45f6-8919-7531ed0994cc.html

Major Shareholding Notification

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

RNS Number : 8846D

Citadel Group

26 June 2023

Ap27

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.             KEY INFORMATION

(a)   Full name of discloser Citadel Group
(b)   Owner or controller of interests and short positions disclosed, if different from 1(a)

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.
N/A
(c)   Name of offeror/offeree in relation to whose relevant securities this form relates

Use a separate form for each offeror/offeree
HORIZON THERAPEUTICS PLC
(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1) N/A
(e)   Date position held/dealing undertaken

For an opening position disclosure, state the latest practicable date prior to the disclosure
23 June 2023
(f)    In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"
N/A

2.             INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Ap28

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(Note 2)

Class of relevant security

(Note 3)
Common Stock ISIN IE00BQPVQZ61
Interests Short positions
Number % Number %
(1)   Relevant securities owned and/or controlled 4,497,297 1.96 220,199 0.09
(2)   Cash-settled derivatives 0 0.00 0 0.00
(3)   Stock-settled derivatives (including options) and agreements to purchase/ sell 1,612,500 0.70 1,479,500 0.64
Total 6,109,797 2.67 1,699,699 0.74

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3.             DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a)           Purchases and sales

Class of relevant

security
Purchase/sale Number of

securities
Price per unit

(Note 5)
Common Buy Transaction 41 101.1268 USD
Common Buy Transaction 245 101.1269 USD
Common Buy Transaction 114 101.1269 USD
Common Buy Transaction 10,000 102.2514 USD
Common Buy Transaction 12,278 102.3050 USD
Common Buy Transaction 602 102.6335 USD
Common Buy Transaction 1,869 102.7398 USD
Common Buy Transaction 535 102.9070 USD
Common Buy Transaction 100 102.9900 USD
Common Buy Transaction 43,542 103.1090 USD
Common Buy Transaction 855 103.1705 USD
Common Buy Transaction 19,471 103.2205 USD
Common Buy Transaction 100 103.7500 USD
Common DVP Transaction 795 102.5600 USD
Common RVP Transaction 795 102.5600 USD
Common Sell Transaction 87 102.0900 USD
Common Sell Transaction 15 102.1500 USD
Common Sell Transaction 100 102.2100 USD
Common Sell Transaction 772 102.2911 USD
Common Sell Transaction 300 102.3183 USD
Common Sell Transaction 405 102.5131 USD
Common Sell Transaction 1,035 102.5145 USD
Common Sell Transaction 210 102.5153 USD
Common Sell Transaction 795 102.5600 USD
Common Sell Transaction 282 102.6072 USD
Common Sell Transaction 1,349 102.6080 USD
Common Sell Transaction 514 102.6083 USD
Common Sell Transaction 437 102.6108 USD
Common Sell Transaction 2,097 102.6123 USD
Common Sell Transaction 792 102.6135 USD
Common Sell Transaction 303 102.6250 USD
Common Sell Transaction 992 102.6312 USD
Common Sell Transaction 825 102.6314 USD
Common Sell Transaction 4,779 102.6314 USD
Common Sell Transaction 1,818 102.6315 USD
Common Sell Transaction 174 102.6326 USD
Common Sell Transaction 321 102.6339 USD
Common Sell Transaction 843 102.6340 USD
Common Sell Transaction 174 102.6341 USD
Common Sell Transaction 172 102.7069 USD
Common Sell Transaction 829 102.7071 USD
Common Sell Transaction 315 102.7072 USD
Common Sell Transaction 449 102.7353 USD
Common Sell Transaction 1,207 102.7542 USD
Common Sell Transaction 250 102.7546 USD
Common Sell Transaction 459 102.7565 USD
Common Sell Transaction 250 102.7879 USD
Common Sell Transaction 399 102.7929 USD
Common Sell Transaction 1,949 102.7958 USD
Common Sell Transaction 1,196 102.7977 USD
Common Sell Transaction 752 102.8006 USD
Common Sell Transaction 460 102.8051 USD
Common Sell Transaction 475 102.8195 USD
Common Sell Transaction 156 102.8825 USD
Common Sell Transaction 756 102.8883 USD
Common Sell Transaction 291 102.8941 USD
Common Sell Transaction 1,180 102.9144 USD
Common Sell Transaction 5,687 102.9183 USD
Common Sell Transaction 2,171 102.9241 USD
Common Sell Transaction 2,434 103.0774 USD
Common Sell Transaction 11,422 103.5935 USD
Common Sell Transaction 24,729 103.6280 USD
Common Sell Transaction 22,852 103.6321 USD
Common Sell Transaction 454 103.9009 USD
Common Sell Transaction 300 104.0900 USD

Ap29

(b)           Cash-settled derivative transactions

Class of

relevant

security
Product

description

e.g. CFD
Nature of dealing

e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position
Number of

reference

securities

(Note 6)
Price

per unit

(Note 5)

(c)           Stock-settled derivative transactions (including options)

(i)            Writing, selling, purchasing or varying

Class of

relevant

security
Product

description e.g. call

option
Writing, purchasing, selling, varying

etc.
Number

of

securities

to which

option

relates

(Note 6)
Exercise

price per

unit
Type

e.g.

American,

European

etc.
Expiry

date
Option

money

paid/

received per unit
Common Call Option Buy Transaction 3,000 110.0000 USD American 2023-Aug-18 1.2000 USD
Common Call Option DVP Transaction 1,250 115.0000 USD American 2023-Jul-21 0.4092 USD
Common Call Option DVP Transaction 1,250 110.0000 USD American 2023-Jul-21 0.9977 USD
Common Call Option RVP Transaction 1,250 115.0000 USD American 2023-Jul-21 0.4092 USD
Common Call Option RVP Transaction 1,250 110.0000 USD American 2023-Jul-21 0.9977 USD

(ii)           Exercise

Class of

relevant

security
Product

description

e.g. call

option
Exercising/

exercised

against
Number of

securities
Exercise

price per

unit

(Note 5)

(d)           Other dealings (including transactions in respect of new securities) (Note 3)

Class of

relevant

security
Nature of dealing

e.g. subscription,

conversion, exercise
Details Price per unit (if

applicable)

(Note 5)

Ap30

4.             OTHER INFORMATION

(a)           Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"
None

(b)           Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.
None

(c)           Attachments

Is a Supplemental Form 8 attached? YES
Date of disclosure 26 June 2023
Contact name Paula Sharp
Telephone number 020 7645 9700

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

Ap32

SUPPLEMENTAL FORM 8

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1, RULE 8.3, RULE 38.5(b) AND

RULE 38.6 OF THE IRISH TAKEOVER PANEL ACT, 1997,

TAKEOVER RULES, 2022

DETAILS OF OPEN STOCK-SETTLED DERIVATIVE (INCLUDING

OPTION) POSITIONS, AGREEMENTS TO PURCHASE OR SELL AND

RIGHTS TO SUBSCRIBE FOR NEW SECURITIES

1.             KEY INFORMATION

Full name of person making

disclosure:
Citadel Group
Name of offeror/offeree in relation

to whose relevant securities the

disclosure relates:
HORIZON THERAPEUTICS PLC

2.             STOCK-SETTLED DERIVATIVES (INCLUDING OPTIONS)

Class of

relevant

security
Product

description

e.g. call

option
Written or

purchased
Number of

securities to

which option

or derivative

relates
Exercise

price

per unit
Type

e.g.

American,

European

etc.
Expiry

date
Common Put Option Purchased -18,700 80.0 USD American 18/08/2023
Common Call Option Purchased 50,000 115.0 USD American 18/08/2023
Common Put Option Purchased -42,400 85.0 USD American 18/08/2023
Common Put Option Purchased -62,500 70.0 USD American 19/01/2024
Common Put Option Purchased -15,000 90.0 USD American 18/08/2023
Common Put Option Purchased -280,000 80.0 USD American 15/12/2023
Common Put Option Purchased -74,700 100.0 USD American 18/08/2023
Common Call Option Purchased 11,100 105.0 USD American 18/08/2023
Common Put Option Sold 4,400 60.0 USD American 18/08/2023
Common Put Option Sold 52,000 55.0 USD American 15/09/2023
Common Put Option Sold 62,500 90.0 USD American 19/01/2024
Common Put Option Sold 700 50.0 USD American 19/01/2024
Common Put Option Sold 338,300 100.0 USD American 21/07/2023
Common Call Option Sold -269,200 105.0 USD American 21/07/2023
Common Put Option Sold 32,800 55.0 USD American 17/11/2023
Common Put Option Sold 280,000 90.0 USD American 21/07/2023
Common Call Option Sold -12,000 100.0 USD American 21/07/2023
Common Put Option Sold 779,900 95.0 USD American 18/08/2023
Common Call Option Sold -5,000 120.0 USD American 18/08/2023
Common Put Option Sold 700 60.0 USD American 17/11/2023
Common Call Option Sold -700,000 110.0 USD American 18/08/2023
Common Put Option Sold 100 65.0 USD American 21/07/2023

3.             AGREEMENTS TO PURCHASE OR SELL

Full details should be given so that the nature of the interest or position can be fully understood:

Ap33

4.             RIGHTS TO SUBSCRIBE FOR NEW SECURITIES (INCLUDING DIRECTORS' AND OTHER EMPLOYEE OPTIONS)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

It is not necessary to provide details on a Supplemental Form with regard to cash-settled derivatives.

The currency of all prices and other monetary amounts should be stated.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to "the Rules" are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ITPPPUMCQUPWURQ